natgillin/translations-raw huggingface dataset:
In patients with relapsed/refractory CLL, the incidence of grade 3/4 hepatitis B infection (reactivation and primary infection) was 2% in R-FC vs 0% FC.
U bolesnika s relapsirajućim/refraktornim KLL-om incidencija hepatitis B infekcije stupnja 3/4 (reaktivacija i primarna infekcija) iznosila je 2% kod primjene R-FC terapije u odnosu na 0% kod primjene FC terapije.
In patients with renal angiomyolipoma, the kidney tumour shrank by at least half in 42% of patients (33 out of 79 patients) treated with Votubia, compared with none of the 39 patients who received placebo.
U bolesnika s renalnim angiomiolipomom, tumor bubrega smanjio se za pola u 42 % bolesnika (33 od 79 bolesnika) liječenih lijekom Votubia, što nije zabilježeno niti kod jednog od 39 bolesnika koji su primili placebo.
In patients with renal angiomyolipoma, the recommended dose is 10 mg once a day.
U bolesnika s renalnim angiomiolipomom preporučena je doza od 10 mg jednom dnevno.
In patients with renal disorders:
U bolesnika s poremećajima rada bubrega:
In patients with renal failure or hepatic impairment, the pharmacokinetics of granisetron were determined following a single 40 g/kg intravenous dose of granisetron hydrochloride.
U bolesnika sa zatajenjem bubrega ili oštećenjem funkcije jetre, farmakokinetika granisetrona procjenjivana je nakon jedne intravenske doze od 40 g/kg granisetronklorida.
In patients with renal impairment accumulation occurs relative to the degree of impairment.
U bolesnika s oštećenjem bubrežne funkcije se nakupljanje pojavljuje srazmjerno stupnju oštećenja.
In patients with renal impairment in whom Mycophenolate mofetil Teva and ganciclovir or its prodrugs, e.g. valganciclovir, are co-administered the dose recommendations for ganciclovir should be observed and patients monitored carefully.
Kod bolesnika s oštećenjem bubrega kod kojih se istodobno primjenjuju Mikofenolat mofetil Teva i ganciklovir ili njegovi predlijekovi, npr. valganciklovir, treba razmotriti primjenu preporučene doze ganciklovira i pažljivo nadzirati bolesnika.
In patients with renal impairment, close monitoring of estimated creatinine clearance is advised.
Savjetuje se pažljivo praćenje procijenjenog klirensa kreatinina kod bolesnika s oštećenom funkcijom bubrega.
In patients with renal impairment, increased exposure to enoxaparin sodium is associated with an increased risk of bleeding.
U bolesnika s oštećenom funkcijom bubrega, povećana izloženost enoksaparin-natriju povezana je s povećanim rizikom od krvarenja.
In patients with renal impairment, increased exposure to enoxaparin sodium is associated with an increased risk of bleeding.
U bolesnika s oštećenom funkcijom bubrega, povećana izloženost enoksaparinnatriju povezana je s povećanim rizikom od krvarenja.
In patients with renal impairment, the maximum daily dose should be 18 mg.
U bolesnika s oštećenjem bubrega, maksimalna dnevna doza treba iznositi 18 mg.
In patients with renal impairment, the systemic exposure to concomitant medicinal products that are primarily excreted via the kidney may increase.
U bolesnika s oštećenjem bubrega, sistemska izloženost lijekovima koji se prvenstveno izlučuju putem bubrega, može se povećati
In patients with renal risk factors, the co-administration of tenofovir disoproxil fumarate with a boosted protease inhibitor should be carefully evaluated.
U pacijenata s bubrežnim čimbenicima rizika treba pažljivo procijeniti istovremenu primjenu tenofovirdizoproksilfumarata s pojačanim inhibitorom proteaze.
In patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriasis arthritis or psoriasis vulgaris, administration of folic or folinic acid may reduce methotrexate toxicity (gastrointestinal symptoms, inflammation of oral mucosa, hair loss and increase of liver enzymes) (see section 4.5).
U bolesnika s reumatoidnim artritisom, poliartikularnim juvenilnim idiopatskim artritisom, psorijatičnim artritisom ili vulgarnom psorijazom, primjena folatne ili folinatne kiseline može smanjiti toksičnost metotreksata (gastrointestinalne simptome, upalu sluznice usne šupljine, ispadanje kose i povišenje jetrenih enzima) (vidjeti dio 4.5).
In patients with rheumatoid arthritis, premedication with 100 mg intravenous methylprednisolone should be completed 30 minutes prior to MabThera infusions to decrease the incidence and severity of infusion related reactions (IRRs).
U bolesnika s reumatoidnim artritisom treba primijeniti premedikaciju metilprednizolonom u dozi od 100 mg intravenski radi smanjenja incidencije i težine reakcija povezanih s infuzijom, a primjena mora završiti 30 minuta prije početka infuzije lijeka MabThera.
In patients with SCN
Bolesnici s teškom kroničnom neutropenijom
In patients with secondary hyperparathyroidism Renvela should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Bolesnici sa sekundarnom hiperparatireozom trebaju uzimati lijek Renvela u sklopu multiterapijskog pristupa koji može uključivati nadomjestke kalcija te 1,25-dihidroksi vitamin D3 ili neki od njegovih analoga kako bi se snizila razina intaktnog paratiroidnog hormona (iPTH).
In patients with secondary hyperparathyroidism Renvela should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Bolesnici sa sekundarnom hiperparatireozom trebaju uzimati lijek Renvela u sklopu multiterapijskog pristupa koji može uključivati nadomjestke kalcija te 1,25-dihidroksi vitamin D3 ili neki od njegovih analoga, kako bi se snizila razina intaktnog paratiroidnog hormona (iPTH).
In patients with secondary hyperparathyroidism Renvela should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25 – dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Bolesnici sa sekundarnom hiperparatireozom trebaju uzimati lijek Renvela u sklopu multiterapijskog pristupa koji može uključivati nadomjestke kalcija te 1,25- dihidroksi vitamin D3 ili neki od njegovih analoga kako bi se snizile razine intaktnog paratiroidnog hormona (iPTH).
In patients with secondary hyperparathyroidism Renvela should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25 – dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Bolesnici sa sekundarnom hiperparatireozom trebaju uzimati lijek Renvela u sklopu multiterapijskog pristupa koji može uključivati nadomjestke kalcija te 1,25- dihidroksi vitamin D3 ili neki od njegovih analoga, kako bi se snizile razine intaktnog paratiroidnog hormona (iPTH).
In patients with secondary hyperparathyroidism Sevelamer carbonate Zentiva should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Bolesnici sa sekundarnom hiperparatireozom trebaju uzimati lijek Sevelamer carbonate Zentiva u sklopu multiterapijskog pristupa koji može uključivati nadomjestke kalcija te 1,25-dihidroksi vitamin D3 ili neki od njegovih analoga, kako bi se snizila razina intaktnog paratiroidnog hormona (iPTH).
In patients with secondary hyperparathyroidism Sevelamer carbonate Zentiva should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Bolesnici sa sekundarnom hiperparatireozom trebaju uzimati Sevelamer carbonate Zentiva u sklopu multiterapijskog pristupa koji može uključivati nadomjestke kalcija te 1,25-dihidroksi vitamin D3 ili neki od njegovih analoga kako bi se snizila razina intaktnog paratiroidnog hormona (iPTH).
In patients with SEGA, everolimus Cmin was approximately dose-proportional within the dose range from 1.35 mg/m2 to 14.4 mg/m2.
U bolesnika oboljelih od SEGA-e, Cmin everolimusa bio je otprilike proporcionalan dozi unutar raspona doze od 1,35 mg/m2 do 14,4 mg/m2.
In patients with severe active infection, a delay in initiation of Zinbryta therapy should be considered (see section 4.8).
U bolesnika s teškom aktivnom infekcijom, treba uzeti u obzir odgodu početka liječenja Zinbrytom (vidjeti dio 4.8).
In patients with severe chronic neutropenia (SCN)
Bolesnici s teškom kroničnom neutropenijom
In patients with severe chronic neutropenia (SCN) Congenital neutropenia
Bolesnici s teškom kroničnom neutropenijom Kongenitalna neutropenija
In patients with severe hepatic impairment (Child-Pugh C) or severe renal impairment (Creatinine Clearance < 30 mL/min/1.73m2), the potential risks associated with the use of this medicine should be assessed against the medical need (see section 5.2).
U bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh C) ili teškim oštećenjem funkcije bubrega (klirens kreatinina <30 ml/min/1,73m2), potencijalne rizike povezane s primjenom ovog lijeka treba procijeniti u odnosu na medicinsku potrebu (vidjeti dio 5.2).
In patients with severe hepatic impairment (Child-Pugh class C), fingolimod- phosphate Cmax was decreased by 22% and AUC was not substantially changed.
U bolesnika s teškim oštećenjem jetre (Child-Pugh stadij C), Cmax fingolimodfosfata bio je smanjen za 22%, a AUC nije bio znatno promijenjen.
In patients with severe hepatic impairment,
Bolesnici s teškim oštećenjem funkcije jetre,
In patients with severe hepatic impairment,
Bolesnici s teškim oštećenjem jetre,
In patients with severe hepatic impairment, reduction in maintenance dose by one half is recommended based on decreased clearance (see sections 4.2 and 5.2).
U bolesnika s teškim oštećenjem funkcije jetre preporučuje se smanjenje doze održavanja na jednu polovicu na temelju smanjenog klirensa (vidjeti dijelove 4.2 i 5.2).
In patients with severe hepatic impairment, reduction in maintenance dose by one-half is recommended based on decreased clearance (see sections 4.2 and 5.2).
U bolesnika s teškim oštećenjem funkcije jetre preporučuje se smanjenje doze održavanja na jednu polovicu na temelju smanjenog klirensa (vidjeti dijelove 4.2 i 5.2).
In patients with severe hepatic impairment, reduction in maintenance dose by one-half is recommended based on decreased clearance (see sections 4.2 and 5.2).
U bolesnika s teškim oštećenjem funkcije jetre preporučuje se smanjenje doze održavanja na jednu polovicu na temelju smanjenog klirensa (vidjeti dijelove 4.2. i 5.2.).
In patients with severe hepatic impairment.
Bolesnici s teškim oštećenjem jetre.
In patients with severe leukopenia, neutropenia, or thrombocytopenia,
Bolesnici s teškom leukopenijom, neutropenijom ili trombocitopenijom,
In patients with severe leukopenia, neutropenia, or thrombocytopenia.
Bolesnici s teškom leukopenijom, neutropenijom ili trombocitopenijom.
In patients with severe renal impairment (20 mL/min  CrCl  40 mL/min) the recommended dose is 250 mg/m² every 3 weeks (see section 5.2).
U bolesnika s teškim oštećenjem bubrega (20 mL/min  CrCl  40 mL/min) preporučena je doza 250 mg/m² svaka 3 tjedna (vidjeti dio 5.2).
In patients with severe renal impairment (CLCR ≤30 ml/min) and in patients with endstage renal disease, a maximum maintenance dose of 250 mg/day is recommended.
Kod bolesnika s teškim oštećenjem bubrega (CLCR ≤ 30 ml/min) i kod bolesnika s terminalnim stadijem bubrežne bolesti preporučuje se maksimalna doza održavanja od 250 mg/dan.
In patients with severe renal impairment (CLCR ≤30 ml/min) and in patients with endstage renal disease, a maximum maintenance dose of 250 mg/day is recommended..
Kod bolesnika s teškim oštećenjem bubrega (CLCR ≤ 30 ml/min) i kod bolesnika s terminalnim stadijem bubrežne bolesti preporučuje se maksimalna doza održavanja od 250 mg/dan.
In patients with severe renal impairment (CLCR ≤30 ml/min) and in patients with endstage renal disease,a maximum maintenance dose of 250 mg/day is recommended.
Kod bolesnika s teškim oštećenjem bubrega (CLCR ≤ 30 ml/min) i kod bolesnika s terminalnim stadijem bubrežne bolesti preporučuje se maksimalna doza održavanja od 250 mg/dan.
In patients with severe renal impairment (CrCL <30 mL/min, calculated by the Cockroft-Gault formula), the recommended dose of bosutinib is 300 mg daily (see sections 4.4 and 5.2).
U bolesnika s teškim oštećenjem funkcije bubrega (CrCL <30 ml/min, izračunato Cockroft-Gaultovom formulom), preporučena doza je 300 mg bosutiniba dnevno (vidjeti dijelove 4.4 i 5.2).
In patients with severe renal impairment (creatinine clearance 15–30 mL/min), plasma concentrations of bosentan decreased by approximately 10%.
U bolesnika s teškim smanjenjem bubrežne funkcije (klirens kreatinina je 15–30 ml/min), koncentracije bosentana u plazmi smanjile su se za oko 10%.
In patients with severe renal impairment (creatinine clearance 5 – 29 ml/min) daily dose should be 10 mg (1 ml solution, equivalent to two pump actuations) per day.
Kod bolesnika s teškim oštećenjem bubrebubrežne funkcije (klirens kreatinina 5-29 ml/min) dnevna doza bi trebala biti 10 mg (1 ml otopine, što odgovara dva potiska pumpice) na dan.
In patients with severe renal impairment (creatinine clearance 5 – 29 ml/min) daily dose should be 10 mg per day.
Kod bolesnika s teškim oštećenjem bubrega (klirens kreatinina 5 - 29 ml/min) dnevna doza bi trebala biti 10 mg dnevno.
In patients with severe renal impairment (creatinine clearance 5 – 29 ml/min) daily dose should be 10 mg per day.
Kod bolesnika s teškim oštećenjem bubrega (klirens kreatinina 5 – 29 ml/min) dnevna doza bi trebala biti 10 mg dnevno.
In patients with severe renal impairment (creatinine clearance 5 – 29 ml/min) daily dose should be 10 mg per day.
Kod bolesnika s teškim oštećenjem bubrega (klirens kreatinina 5-29 ml/min) dnevna doza bi trebala biti 10 mg dnevno.
In patients with severe renal impairment (creatinine clearance 5 – 29 ml/min) daily dose should be 10 mg per day.
Kod bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina 5-29 ml/min) dnevna doza bi trebala biti 10 mg dnevno.
In patients with severe renal impairment (creatinine clearance 5-29 ml/min) daily dose should be 10 mg per day.
Kod bolesnika s teškim oštećenjem bubrega (klirens kreatinina 5-29 ml/min) dnevna doza bi trebala biti 10 mg na dan.
In patients with severe renal impairment (creatinine clearance < 30 ml/min) administered 1microgram/kg/min , 80 % inhibition was achieved in more than 80 % of patients at 24 hours.
U bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina < 30 ml/min) u kojih je primijenjen lijek u dozi od mikrogram/kg/min, nakon 24 sata postignuta je 80 % -tna inhibicija u više od 80 % bolesnika.
In patients with severe renal impairment (creatinine clearance < 30 ml/min) and in patients who require haemodialysis use of tenofovir disoproxil fumarate is not recommended.
U pacijenta s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min) i pacijenta kojima je potrebna hemodijaliza ne preporučuje se primjena tenofovirdizoproksilfumarata.
In patients with severe renal impairment (creatinine clearance < 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6-fold on average) which may lead to an increased bleeding risk.
U bolesnika s teško oštećenom funkcijom bubrega (klirens kreatinina manji 30 ml/min) mogu se značajno povisiti razine rivaroksabana u plazmi (prosječno 1,6 puta), što može dovesti do povećanog rizika od krvarenja.
In patients with severe renal impairment (creatinine clearance < 30 ml/min.) or patients who may be predisposed to fluid retention parecoxib should be initiated at the lowest recommended dose (20 mg) and the patient's kidney function should be closely monitored (see sections 4.4 and 5.2).
U bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min.) ili u bolesnika koji mogu biti skloni zadržavanju tekućine, primjena parekoksiba mora se započeti u najnižoj preporučenoj dozi (20 mg), a funkcija bubrega bolesnika mora se pažljivo nadzirati (vidjeti dijelove 4.4 i 5.2).
In patients with severe renal impairment (creatinine clearance < 30 ml/min.) or patients who may be predisposed to fluid retention parecoxib should be initiated at the lowest recommended dose (20 mg) and the patient's kidney function should be closely monitored (see sections 4.4 and 5.2).
U bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min.) ili u bolesnika koji mogu biti skloni zadržavanju tekućine, primjena parekoksiba mora se započeti u najnižoj preporučenoj dozi (20 mg), a funkcija bubrega bolesnika pažljivo nadzirati (vidjeti dijelove 4.4 i 5.2).
In patients with severe renal impairment (creatinine clearance below 30 ml/min),
Bolesnici s teškim oštećenjem bubrežne funkcije (klirens kreatinina manji od 30 ml/min),
In patients with severe renal impairment (creatinine clearance below 30 ml/min).
Bolesnici s teškim oštećenjem bubrežne funkcije (klirens kreatinina manji od 30 ml/min).
In patients with severe renal impairment (creatinine clearance less than 30 mL/min), the dose of methylnaltrexone bromide should be reduced from 12 mg to 8 mg (0.4 mL of solution) for those weighing 62 to 114 kg.
Kod bolesnika s teškim oštećenjem bubrega (klirens kreatinina manji od 30 ml/min), a koji teže od 62 do 114 kg, doza metilnaltreksonbromida mora se smanjiti s 12 mg na 8 mg (0,4 ml otopine).
In patients with severe renal impairment (eGFR <30 ml/min/1.73 m2), including those with end-stage renal disease requiring dialysis, Enurev Breezhaler should only be used in the expected benefit outweighs the potential risk (see section 4.4).
U bolesnika s teškim oštećenjem bubrega (eGFR <30 ml/min/1,73 m2), uključujući one s bolešću bubrega u završnoj fazi koja zahtijeva dijalizu, Enurev Breezhaler treba koristiti samo ako očekivana korist premašuje potencijalni rizik (vidjeti dio 4.4).
In patients with severe renal impairment (eGFR <30 ml/min/1.73 m2), including those with end-stage renal disease requiring dialysis, Seebri Breezhaler should only be used in the expected benefit outweighs the potential risk (see section 4.4).
U bolesnika s teškim oštećenjem bubrega (eGFR <30 ml/min/1,73 m2), uključujući one s bolešću bubrega u završnoj fazi koja zahtijeva dijalizu, Seebri Breezhaler treba koristiti samo ako očekivana korist premašuje potencijalni rizik (vidjeti dio 4.4).
In patients with severe renal impairment (eGFR <30 ml/min/1.73 m2), including those with end-stage renal disease requiring dialysis, Tovanor Breezhaler should only be used in the expected benefit outweighs the potential risk (see section 4.4).
U bolesnika s teškim oštećenjem bubrega (eGFR <30 ml/min/1,73 m2), uključujući one s bolešću bubrega u završnoj fazi koja zahtijeva dijalizu, Tovanor Breezhaler treba koristiti samo ako očekivana korist premašuje potencijalni rizik (vidjeti dio 4.4).
In patients with severe renal impairment or end-stage renal disease requiring dialysis Enurev Breezhaler should be used only if the expected benefit outweighs the potential risk (see sections 4.4 and 5.2).
U bolesnika s teškim oštećenjem bubrega ili bolešću bubrega u završnoj fazi koja zahtijeva dijalizu Enurev Breezhaler smije se koristiti samo ako očekivane koristi premašuju potencijalni rizik (vidjeti dijelove 4.4 i 5.2).
In patients with severe renal impairment or end-stage renal disease requiring dialysis Seebri Breezhaler should be used only if the expected benefit outweighs the potential risk (see sections 4.4 and 5.2).
U bolesnika s teškim oštećenjem bubrega ili bolešću bubrega u završnoj fazi koja zahtijeva dijalizu Seebri Breezhaler smije se koristiti samo ako očekivane koristi premašuju potencijalni rizik (vidjeti dijelove 4.4 i 5.2).
In patients with severe renal impairment or end-stage renal disease requiring dialysis Tovanor Breezhaler should be used only if the expected benefit outweighs the potential risk (see sections 4.4 and 5.2).
U bolesnika s teškim oštećenjem bubrega ili bolešću bubrega u završnoj fazi koja zahtijeva dijalizu Tovanor Breezhaler smije se koristiti samo ako očekivane koristi premašuju potencijalni rizik (vidjeti dijelove 4.4 i 5.2).
In patients with severe renal impairment or ESRD, plasma concentrations may be increased due to alteration of drug absorption, distribution and/or metabolism secondary to renal dysfunction.
U pacijenata s teškim oštećenjem bubrega ili terminalnom stadiju bolesti bubrega, koncentracije u plazmi mogu biti povećane zbog promjena u apsorpciji, distribuciji i/ili metabolizmu lijeka koje nastaju sekundarno poremećaju funkcije bubrega.
In patients with severe renal impairment, the AUC0- of total aprepitant (unbound and protein bound) decreased by 21 % and Cmax decreased by 32 %, relative to healthy subjects.
U ispitanika s teškim oštećenjem funkcije bubrega AUC0-∞ ukupnog aprepitanta (slobodnog i vezanog na proteine) snizio se za 21%, a Cmax za 32% u odnosu na zdrave ispitanike.
In patients with severe renal impairment, the concomitant use of cimetidine and varenicline should be avoided.
U bolesnika s teškim oštećenjem bubrežne funkcije treba izbjegavati istodobnu primjenu cimetidina i vareniklina.
In patients with severely reduced liver function Kalydeco should only be started if the benefits outweigh the risks.
Ne preporučuje se primjena lijeka Kalydeco u bolesnika s teškim oštećenjem jetre osim ako je korist veća od rizika.
In patients with Sickle Cell Syndrome hydroxycarbamide was eliminated with a half-life of approximately six to seven hours, which is longer than reported in other indications.
Kod bolesnika sa sindromom srpastih stanica poluvijek eliminacije hidroksikarbamida bio je oko šest do sedam sati, što je duže od poluvijeka zabilježenog kod drugih indikacija.
In patients with solid tumours and with moderately impaired hepatic function (Child-Pugh score 7-9), geometric mean erlotinib AUC0-t and Cmax was 27000 ng•h/mL and 805 ng/mL, respectively, as compared to 29300 ng•h/mL and 1090 ng/mL in patients with adequate hepatic function including patients with primary liver cancer or hepatic metastases.
U bolesnika sa solidnim tumorima i umjerenim oštećenjem funkcije jetre (Child-Pugh indeks 7 – 9) geometrijska sredina AUC0-t erlotiniba iznosila je 27 000 ng•h/ml, a Cmax 805 ng/ml u usporedbi s 29 300 ng•h/ml odnosno 1090 ng/ml u bolesnika s odgovarajućom funkcijom jetre, uključujući bolesnike s primarnim rakom jetre ili metastazama u jetri.
In patients with ST segment elevation acute myocardial infarction: Therapy should be started as early as possible after symptoms start and continued for at least four weeks.
Kod bolesnika s akutnim infarktom miokarda s elevacijom ST segmenta: liječenje je potrebno započeti čim je ranije moguće nakon pojave simptoma i nastaviti kroz najmanje četiri tjedna.
In patients with stable coronary artery disease (CAD) on ASA, ticagrelor demonstrates a rapid onset of pharmacological effect as demonstrated by a mean inhibition of platelet aggregation (IPA) for ticagrelor at 0.5 hours after 180 mg loading dose of about 41%, with the maximum IPA effect of 89% by 2-4 hours post dose, and maintained between 2-8 hours.
U bolesnika sa stabilnom bolesti koronarnih arterija na acetilsalicilatnoj kiselini, tikagrelor pokazuje brz nastup farmakološkog učinka kako je pokazano srednjom vrijednošću inhibicije agregacije trombocita (Inhibition of Platelet Aggregation - IPA) od oko 41% za tikagrelor 0,5 sati nakon 180 mg udarne doze, s maksimalnim IPA učinkom od 89% za 2 – 4 sata nakon uzimanja doze, koji je održan između 2 – 8 sati.
In patients with systemic sclerosis and ongoing digital ulcer disease, bosentan improves blood circulation in the fingers and toes, preventing the development of new digital ulcers.
U bolesnika sa sistemskom sklerozom i prisutnom bolešću digitalnih ulceracija, bosentan poboljšava cirkulaciju krvi u prstima na rukama i stopalima, sprječavajući razvoj novih digitalnih ulceracija.